AbbVie’s rheumatoid arthritis drug Humira (adalimumab) and six other drugs whose prices were raised in 2020 without supportive clinical data cost the U.S. health system $1.67 billion in annual drug spending, according to a new analysis released yesterday by the Institute for Clinical and Economic Review (ICER).
Source: Drug Industry Daily